PARK CITY, Utah, Aug. 28, 2018 /PRNewswire-PRWeb/ -- InterveneRx is proud to announce a partnership with CerpassRx, a leading pharmacy benefits manager (PBM), to offer RxNextCare, an innovative approach in managing the cost and health outcomes associated with specialty drugs for CerpassRx clients and members. RxNextCare provides evidence-based specialty drug care plans that are integrated with a digital therapy mobile application and biometric devices to monitor, engage and manage the care of patients in real-time.
CerpassRx Chief Clinical Officer John Nicolosi, PharmD explains CerpassRx's decision to proceed with the InterveneRx relationship, "Specialty medications continue to be a significant cost driver within the pharmacy industry. CerpassRx is continuously evaluating innovative opportunities to deliver value to our clients and improve the care of our members. The InterveneRx program is unique in the market in engaging and monitoring members on specialty medications, and we are excited to offer this program to deliver better health outcomes while providing savings to our clients."
"We believe the InterveneRx platform fills a significant gap in identifying the clinical value, safety and effectiveness of specialty drugs. We are pleased that a forward thinking organization such as CerpassRx will be implementing this platform to monitor and manage their specialty drug patients," said InterveneRx CEO Mark Steck, Pharm D, MBA.
CerpassRx expects to roll the RxNextCare program out to its clients within the next 30 days.
About CerpassRx CerpassRx is a leading pharmacy benefits management company based in Dallas-Fort Worth. CerpassRx provides employers with innovative and proactive solutions to manage their membership's prescription benefits. Their flexible, collaborative approach to focusing on their members sets them apart in their industry.
About InterveneRx InterveneRx is a technology enabled care management company focused on monitoring and improving complex care for patients utilizing specialty drugs. InterveneRx has developed the first ever automated specialty drug clinical pathways integrated with a mobile application to engage and manage patients more effectively for improved adherence and health outcomes while reducing adverse events and costs.
SOURCE InterveneRx
Advertisement
CerpassRx Chief Clinical Officer John Nicolosi, PharmD explains CerpassRx's decision to proceed with the InterveneRx relationship, "Specialty medications continue to be a significant cost driver within the pharmacy industry. CerpassRx is continuously evaluating innovative opportunities to deliver value to our clients and improve the care of our members. The InterveneRx program is unique in the market in engaging and monitoring members on specialty medications, and we are excited to offer this program to deliver better health outcomes while providing savings to our clients."
Advertisement
"We believe the InterveneRx platform fills a significant gap in identifying the clinical value, safety and effectiveness of specialty drugs. We are pleased that a forward thinking organization such as CerpassRx will be implementing this platform to monitor and manage their specialty drug patients," said InterveneRx CEO Mark Steck, Pharm D, MBA.
CerpassRx expects to roll the RxNextCare program out to its clients within the next 30 days.
About CerpassRx CerpassRx is a leading pharmacy benefits management company based in Dallas-Fort Worth. CerpassRx provides employers with innovative and proactive solutions to manage their membership's prescription benefits. Their flexible, collaborative approach to focusing on their members sets them apart in their industry.
About InterveneRx InterveneRx is a technology enabled care management company focused on monitoring and improving complex care for patients utilizing specialty drugs. InterveneRx has developed the first ever automated specialty drug clinical pathways integrated with a mobile application to engage and manage patients more effectively for improved adherence and health outcomes while reducing adverse events and costs.
SOURCE InterveneRx
